ARROWHEAD PHARMACEUTICALS, INC. Annual Report - How They Did This Year

Hey there! Let's take a look at how ARROWHEAD PHARMACEUTICALS, INC. performed this past year, ending September 30, 2025. It's been a busy period with some significant developments that show the company is actively investing in its future and strengthening its partnerships.

Building for the Future: New Manufacturing Facility!

One of the biggest highlights this year is the completion and reclassification of a major construction project. The company has been working on a new manufacturing facility, and during the fiscal year, a significant portion of this "Construction In Progress" was officially moved into the "Building" and "Manufacturing Equipment" categories. This means they've finished building and equipping a key operational asset, which is a big step forward for their production capabilities. They also continued to invest in other essential assets like research equipment, computers, and leasehold improvements to support their ongoing work.

Stronger Together: Key Partnerships and Collaborations

ARROWHEAD PHARMACEUTICALS continues to rely on and expand its network of strategic partnerships, which are crucial for a biotech company. This year saw activity with several important collaborators:

• Sarepta Therapeutics Inc.: There were several developments related to their collaboration agreement, with specific dates noted in February, August, and November 2025.
• Sanofi: A new license agreement with Sanofi was established in August 2025, which could open new avenues for their programs.
• GlaxoSmithKline (GSK): Their existing license agreements, including the GSK HSD License Agreement (from 2021) and the GSK HBV Agreement (from 2023), continued to be active.
• Takeda Pharmaceuticals: The license and co-funding agreement from 2020 remained in place.
• Amgen: The Olpasiran Agreement, which dates back to 2016, also continued through this fiscal year.
• Novartis: The company also has ongoing patent and licensing agreements with Novartis.

These collaborations are vital as they often involve shared development costs, access to broader markets, and validation of ARROWHEAD's technology.

Financial Footing: Raising Capital

To support its growth and research efforts, the company engaged in a private placement in November 2024. This is a way for companies to raise money by selling shares directly to a small number of investors, rather than through a public offering. This indicates they secured additional capital to fund their operations and strategic initiatives. They also continue to manage equity incentive plans for employees.

In summary, ARROWHEAD PHARMACEUTICALS, INC. had a year marked by significant investment in its physical infrastructure, particularly with the completion of a new manufacturing facility. They also maintained and expanded key partnerships, which are essential for a company in the pharmaceutical space, and raised capital to fuel their future endeavors.